These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
834 related articles for article (PubMed ID: 19072714)
1. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Wilcox MH; Tack KJ; Bouza E; Herr DL; Ruf BR; Ijzerman MM; Croos-Dabrera RV; Kunkel MJ; Knirsch C Clin Infect Dis; 2009 Jan; 48(2):203-12. PubMed ID: 19072714 [TBL] [Abstract][Full Text] [Related]
2. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Beibei L; Yun C; Mengli C; Nan B; Xuhong Y; Rui W Int J Antimicrob Agents; 2010 Jan; 35(1):3-12. PubMed ID: 19900794 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Jaksic B; Martinelli G; Perez-Oteyza J; Hartman CS; Leonard LB; Tack KJ Clin Infect Dis; 2006 Mar; 42(5):597-607. PubMed ID: 16447103 [TBL] [Abstract][Full Text] [Related]
4. Linezolid for the treatment of infections caused by Gram-positive pathogens in China. Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341 [TBL] [Abstract][Full Text] [Related]
5. Linezolid for the treatment of complicated skin and skin structure infections in children. Yogev R; Patterson LE; Kaplan SL; Adler S; Morfin MR; Martin A; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S172-7. PubMed ID: 14520143 [TBL] [Abstract][Full Text] [Related]
6. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. Wilcox M; Nathwani D; Dryden M J Antimicrob Chemother; 2004 Feb; 53(2):335-44. PubMed ID: 14729745 [TBL] [Abstract][Full Text] [Related]
7. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Jantausch BA; Deville J; Adler S; Morfin MR; Lopez P; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S164-71. PubMed ID: 14520142 [TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250 [TBL] [Abstract][Full Text] [Related]
11. Linezolid more efficacious than vancomycin to eradicate infecting organism in critically ill patients with Gram-positive infections. Sirvent JM; Piñeiro L; de la Torre M; Motjé M; de Batlle J; Bonet A Rev Esp Quimioter; 2010 Mar; 23(1):27-35. PubMed ID: 20232021 [TBL] [Abstract][Full Text] [Related]
12. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. Shorr AF; Kunkel MJ; Kollef M J Antimicrob Chemother; 2005 Nov; 56(5):923-9. PubMed ID: 16195255 [TBL] [Abstract][Full Text] [Related]
13. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Deville JG; Adler S; Azimi PH; Jantausch BA; Morfin MR; Beltran S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S158-63. PubMed ID: 14520141 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis. Bounthavong M; Hsu DI Curr Med Res Opin; 2010 Feb; 26(2):407-21. PubMed ID: 20001574 [TBL] [Abstract][Full Text] [Related]
15. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Stevens DL; Herr D; Lampiris H; Hunt JL; Batts DH; Hafkin B Clin Infect Dis; 2002 Jun; 34(11):1481-90. PubMed ID: 12015695 [TBL] [Abstract][Full Text] [Related]
16. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Puzniak LA; Morrow LE; Huang DB; Barreto JN Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955 [TBL] [Abstract][Full Text] [Related]
17. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients. Chaftari AM; Hachem R; Mulanovich V; Chemaly RF; Adachi J; Jacobson K; Jiang Y; Raad I Int J Antimicrob Agents; 2010 Aug; 36(2):182-6. PubMed ID: 20452752 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]